OTC: ACXIF 21.95%
Underperform Recommendation Issued On ACXIF By RBC Capital
NASDAQ: NGNE 31.15%
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
NASDAQ: PRAA 32.17%
PRA Group (PRAA) Q4 2025 Earnings Call Transcript
NASDAQ: VEEA 30.24%
Veea Shares Surge After Launch of TerraFabric Edge Computing Platform
NASDAQ: BWIN 28.55%
Baldwin (BWIN) Q4 2025 Earnings Call Transcript
NYSE: KORE 77.39%
KORE Reports Third Quarter 2025 Results
NYSE: ACXIF 31.15%
NYSE: NGNE 31.15%
NYSE: PRAA 31.15%
NYSE: VEEA 31.15%
NYSE: BWIN 31.15%
